Tirzepatide (Mounjaro for T2DM and Zepbound for obesity) is a novel dual agonist that targets both the GLP‐1 and GIP receptors, offering enhanced effects on glucose control and weight loss [19]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.